Belsomra vs Dayvigo: Titration Speed and Tolerability Compared

What Are Suvorexant and Lemborexant?

Both drugs belong to the dual orexin receptor antagonist (DORA) class. They block orexin-1 and orexin-2 receptors in the brain, reducing the wake-promoting signal rather than adding sedation the way benzodiazepines do. That mechanistic difference is why orexin antagonists generally produce less rebound insomnia and physical dependence than older sleep agents.

The FDA approved suvorexant in August 2014, making it the first DORA on the US market. Herring et al. Published the key phase 3 data in Lancet Neurology 2014, reporting that suvorexant 20 mg and 40 mg reduced wake after sleep onset (WASO) and increased total sleep time versus placebo over three months. Lemborexant received FDA approval in December 2019, and its approval package included the first head-to-head DORA comparison ever conducted in a phase 3 setting.

Mechanism Differences That Affect Tolerability

Suvorexant and lemborexant both antagonize OX1R and OX2R, but they differ in receptor binding kinetics. Lemborexant dissociates from the orexin receptor faster than suvorexant does, and that faster off-rate is one proposed explanation for its lower next-day impairment profile. A longer receptor occupancy late into the morning could explain why suvorexant 15 mg produced worse driving-simulation performance than lemborexant 10 mg in SUNRISE-1, even though lemborexant's plasma half-life is actually longer (roughly 17-19 hours vs. Suvorexant's 12 hours).

Approved Doses at a Glance

Suvorexant is available in 5 mg, 10 mg, 15 mg, and 20 mg tablets. The FDA label recommends starting at 10 mg and allowing at least seven days before increasing to 20 mg. Lemborexant comes in 5 mg and 10 mg tablets. The label permits starting at either dose, and no minimum waiting period before increasing to 10 mg is specified, though clinical practice typically reassesses after one to two weeks.

Titration Speed: How Fast Can You Reach an Effective Dose?

Reaching the therapeutic dose faster matters to patients who have spent weeks lying awake, and it matters to prescribers trying to limit the number of follow-up calls in the first month. The titration profiles of these two drugs are meaningfully different.

Suvorexant Titration Schedule

The standard approach with suvorexant:

1. Start at 10 mg taken within 30 minutes of bedtime.
2. Wait at least seven days to assess response.
3. Increase to 20 mg if 10 mg is insufficient.

The FDA label explicitly notes that 20 mg is the maximum dose and cautions that doses above 20 mg are not recommended because of disproportionately increased adverse effects. Clinicians treating patients with moderate hepatic impairment or those taking moderate CYP3A inhibitors should keep the dose at 10 mg. Patients on strong CYP3A inhibitors should avoid suvorexant entirely.

Lemborexant Titration Schedule

Lemborexant's titration is more compressed:

1. Start at 5 mg. For patients who tolerate 5 mg but need more sleep-onset or sleep-maintenance benefit, increase to 10 mg.
2. No mandatory waiting interval is defined in the label, giving prescribers latitude to move to 10 mg within the first one to two weeks.
3. Patients with moderate hepatic impairment should not exceed 5 mg. The drug is contraindicated in severe hepatic impairment.

In practice, many clinicians start directly at 5 mg and reassess at the two-week mark. Some patients respond adequately at 5 mg and never need 10 mg, which is a meaningful advantage for minimizing residual sedation in older adults.

Why the Speed Difference Matters Clinically

A compressed titration means a patient can reach their optimal dose two to three weeks earlier with lemborexant than with suvorexant. For someone experiencing occupational or social impairment from insomnia, that gap is not trivial. The FDA label for suvorexant specifies the seven-day minimum between dose steps; no analogous restriction exists for lemborexant.

SUNRISE-1: The Head-to-Head Trial

SUNRISE-1 is the only phase 3 randomized controlled trial that has directly compared a DORA to another DORA. The full results were published in JAMA Network Open in 2019 (N=291). Understanding what SUNRISE-1 actually measured helps clinicians interpret the titration and tolerability differences rather than relying on cross-trial comparisons.

Study Design

SUNRISE-1 enrolled adults aged 55 and older with insomnia disorder. Participants were randomized to:

• Lemborexant 5 mg nightly
• Lemborexant 10 mg nightly
• Suvorexant 15 mg nightly (the dose approved for that age group)
• Placebo

The primary endpoint was subjective WASO at month 1. Secondary endpoints included sleep onset latency, driving performance, and a battery of next-day psychomotor assessments.

Efficacy Results

At month 1, both lemborexant doses outperformed suvorexant 15 mg on subjective WASO. Lemborexant 5 mg reduced WASO by 41.5 minutes from baseline; lemborexant 10 mg reduced it by 48.6 minutes; suvorexant 15 mg reduced it by 35.2 minutes. The differences between lemborexant 10 mg and suvorexant 15 mg were statistically significant (P<0.05 for the primary endpoint at month 1).

Sleep onset latency also favored lemborexant 10 mg over suvorexant 15 mg, though the lemborexant 5 mg vs. Suvorexant comparison was more modest.

Next-Day Driving Impairment: The Tolerability Story

This is where SUNRISE-1 delivered the most clinically actionable finding. The study used a standardized driving simulation test administered the morning after drug administration. The key measure was Standard Deviation of Lateral Position (SDLP), a validated proxy for lane-keeping ability.

Suvorexant 15 mg produced significantly worse SDLP scores than both lemborexant doses and placebo on the morning-after assessment. Lemborexant 10 mg, despite having a longer plasma half-life than suvorexant 15 mg, caused less driving impairment. The authors attributed this to the faster receptor off-rate of lemborexant, meaning receptor occupancy drops below the impairment threshold earlier in the morning even when plasma drug levels remain detectable.

As the SUNRISE-1 authors noted in the paper: "Lemborexant was associated with significantly less morning-after residual effects on driving than suvorexant, despite similar or greater efficacy on sleep maintenance."

Tolerability Profiles Beyond Next-Day Sedation

SUNRISE-1 captured driving impairment, but the broader tolerability picture requires looking at pooled phase 2/3 data and post-marketing reports.

Somnolence and Dizziness

In the lemborexant phase 3 program (SUNRISE-1 and SUNRISE-2, combined N approximately 900), somnolence was reported in roughly 7-10% of patients on lemborexant 10 mg. Suvorexant's phase 3 data showed somnolence in approximately 7% at 20 mg and 3% at 10 mg. Direct comparison of these rates is limited by different trial populations and assessment methods, but neither drug shows a dramatically higher somnolence signal at their lowest approved doses.

Dizziness occurred in about 3% of lemborexant users at 10 mg in SUNRISE-2, compared to approximately 2% with suvorexant 20 mg in the Herring et al. Trials. Neither difference is large enough to guide drug selection on its own.

Sleep Paralysis and Hypnagogic Hallucinations

Both drugs carry FDA label warnings for sleep paralysis and hypnagogic or hypnopompic hallucinations. These are class effects of DORA therapy and reflect partial activation of REM-like states. Rates in trials were low for both agents, generally below 1-2%, but patients should be counseled before starting either drug.

Complex Sleep Behaviors

The FDA added a boxed warning to all sleep medications, including suvorexant and lemborexant, regarding complex sleep behaviors such as sleepwalking, sleep-driving, and other behaviors performed while not fully awake. This warning applies equally to both agents and is not a differentiating factor between them.

Older Adults: A Special Population

Both drugs have data specifically in adults aged 65 and older. For suvorexant, the same 10 mg starting dose applies, with a maximum of 20 mg. Lemborexant's label actually recommends considering 5 mg as the target dose in many older patients, recognizing that the 10 mg dose, while effective, carries higher next-day sedation risk in this group. The SUNRISE-1 population was exclusively adults aged 55 and older, so its driving impairment findings are directly relevant to the older-adult clinical question.

HealthRX Titration Decision Framework: Suvorexant vs. Lemborexant

| Clinical Factor | Favor Suvorexant | Favor Lemborexant | |---|---|---| | Age 55 or older with driving concerns | No | Yes (SUNRISE-1 SDLP data) | | Need for rapid dose escalation | No (7-day step minimum) | Yes (flexible titration) | | Moderate CYP3A inhibitor co-prescribed | Use 10 mg only | Check CYP3A4 interactions | | Moderate hepatic impairment | 10 mg max | 5 mg max | | Severe hepatic impairment | Avoid | Contraindicated | | Primary complaint: sleep maintenance | Both effective | 10 mg shows greater WASO reduction | | Primary complaint: sleep onset | Both effective | 10 mg showed faster onset in SUNRISE-1 | | Insurance / formulary | Often preferred on legacy plans | Increasingly on formulary post-2020 |

Switching from Belsomra to Dayvigo: When and How

Switching between DORAs within the same class is generally straightforward because there is no pharmacological cross-dependence concern and no documented discontinuation syndrome from suvorexant that would complicate the transition.

Reasons Clinicians Initiate a Switch

The most common reasons a prescriber considers moving a patient from suvorexant to lemborexant include:

• Persistent next-day grogginess on suvorexant 10 mg or 20 mg that has not resolved after four to six weeks
• Inadequate sleep maintenance despite maximum-dose suvorexant
• Concern about morning driving impairment, particularly in older adults
• Formulary change or patient cost preference

How to Switch Safely

No taper is required when stopping suvorexant. The transition can be done on a simple cross-over schedule: the patient takes their last suvorexant dose on night X, then starts lemborexant 5 mg on night X+1. There is no documented pharmacokinetic interaction between the two drugs that would require a washout period, though a one-night pause is sometimes used to minimize any additive residual sedation on the transition day.

The starting dose for a switch patient is typically 5 mg regardless of what suvorexant dose they were on. If the patient was on suvorexant 20 mg and felt the drug was under-performing on sleep maintenance, clinicians may consider starting lemborexant at 5 mg for one to two weeks and reassessing before moving to 10 mg.

Monitoring After Switching

Patients who switch should be reassessed at two weeks for both efficacy and next-day function. A validated tool such as the Insomnia Severity Index (ISI) or the STOP-BANG questionnaire (the latter to screen for concurrent sleep apnea) can structure those follow-up visits. Undiagnosed obstructive sleep apnea is a contraindication to DORA therapy without concurrent treatment, and switching between DORAs does not resolve an underlying OSA issue.

Pharmacokinetics: Why Half-Life Alone Does Not Predict Tolerability

One of the counterintuitive findings from SUNRISE-1 is that lemborexant, which has a longer half-life than suvorexant, produced less next-day impairment. This finding challenges a simple "longer half-life equals more hangover" assumption.

Suvorexant Pharmacokinetics

• Half-life: approximately 12 hours
• Time to peak: 2 hours (range 30 minutes to 6 hours)
• Protein binding: greater than 99%
• Metabolism: primarily CYP3A, minor CYP2C19
• Active metabolites: none of clinical significance

Lemborexant Pharmacokinetics

• Half-life: approximately 17-19 hours
• Time to peak: 1-3 hours
• Protein binding: approximately 94%
• Metabolism: primarily CYP3A4
• Active metabolite: M4 and M9 with weaker orexin receptor activity

The faster receptor dissociation rate of lemborexant means that even as plasma concentrations remain elevated, receptor occupancy at the orexin receptor drops below the functionally impairing threshold before the patient needs to wake up and drive. Suvorexant's tighter receptor binding prolongs clinically meaningful receptor blockade into the morning even as its plasma levels fall. This kinetic-dynamic dissociation is central to interpreting the SUNRISE-1 driving data correctly.

Cost, Formulary, and Access Considerations

Neither suvorexant nor lemborexant has a generic available as of early 2025. Both are branded Schedule IV controlled substances. Suvorexant (Belsomra) has been on the market longer and may appear on some legacy Medicare Part D formularies at a lower tier than lemborexant. GoodRx cash-pay pricing for a 30-tablet supply typically runs between $350 and $420 for both agents, though manufacturer savings programs can reduce out-of-pocket costs significantly for commercially insured patients.

Prescribers should verify formulary tier before initiating either drug, particularly for Medicare Part D beneficiaries, as prior authorization requirements differ by plan. Some insurers require documented failure of at least one other non-controlled sleep agent, such as doxepin 3-6 mg or eszopiclone, before approving a DORA.

Clinical Guidance and Guideline Context

The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline on chronic insomnia treatment lists both suvorexant (at that time the only approved DORA) and cognitive behavioral therapy for insomnia (CBT-I) as options, with a conditional recommendation for pharmacotherapy when CBT-I is unavailable or has failed. The guideline does not address lemborexant, which was approved after its publication.

The European Sleep Research Society and the AASM both position CBT-I as the first-line treatment for chronic insomnia. Pharmacotherapy, including DORAs, is considered when behavioral treatment is insufficient or inaccessible. Neither guideline currently specifies a preference between suvorexant and lemborexant, leaving that choice to clinical judgment informed by data like SUNRISE-1.

As stated in the AASM guideline: "Clinicians should use shared decision-making, considering individual patient factors such as age, comorbidities, and next-day functional demands, when selecting a pharmacological agent for insomnia."

Summary of Key Differentiators

Suvorexant and lemborexant occupy the same mechanistic class and the same Schedule IV category, but the clinical picture separates them in several ways:

• Titration speed. Lemborexant has no mandatory waiting interval between dose steps. Suvorexant requires at least seven days at 10 mg before moving to 20 mg.
• Next-day impairment. SUNRISE-1 showed that suvorexant 15 mg produced significantly worse driving simulation performance than both lemborexant doses in adults aged 55 and older, despite lemborexant having the longer plasma half-life.
• Sleep maintenance efficacy. Lemborexant 10 mg reduced WASO by 48.6 minutes vs. Suvorexant 15 mg's 35.2 minutes in SUNRISE-1.
• Older adults. Lemborexant's label explicitly supports a 5 mg ceiling for many older patients, offering a finer dose-response gradient than suvorexant provides.
• Switching. No washout is needed when moving from suvorexant to lemborexant. Start lemborexant 5 mg on the night after the last suvorexant dose.

For a patient on suvorexant 20 mg who continues to report morning grogginess or inadequate sleep maintenance, a trial of lemborexant starting at 5 mg is a clinically reasonable next step supported by the SUNRISE-1 head-to-head data.